Jul. 10 at 4:01 AM
$KZIA In earlier research - Highly aggressive cancer stem cell phenotypes, (a cancer cell type), develop cancer drug resistance signatures. PI3K–mTOR blockade acts upstream of these damaged pathway mechanisms, to inhibit (repair/restrict ) this breakdown. Thus, pAX overcomes immunotherapy resistance to reduce primary tumor burden, circulating tumor cells, and direct and indirect indicators of metastasis, with a favorable toxicity profile. Gene expression analyses show that paxalisib profoundly affects the immune microenvironment in tumors, reducing adaptive immune phenotypes, associated with immunotherapy resistance. It would seem apparent, and as stated this novel new combo treatment may offer therapeutic direction in PI3K / mTOR dysregulated solid tumor cancer. This is a high impact breakthrough in cancer immunotherapy treatment.
